-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Peripheral T-Cell Lymphoma Not Otherwise Specified and Anaplastic Large Cell Lymphoma

Program: Education Program
Session: Practical Management of T-Cell and Natural Killer Cell Lymphomas
Saturday, December 5, 2015, 9:30 AM-11:00 AM
Hall D, Level 2 (Orange County Convention Center)
Sunday, December 6, 2015, 7:30 AM-9:00 AM
Hall E2, Level 2 (Orange County Convention Center)

Anne W Beaven, MD

Hematologic Malignancies, Duke University Medical Center, Durham, NC

Disclosures: Off Label Use: 1. Brentuximab vedotin in peripheral T cell lymphoma, NOS 2. Crizotinib in ALK+ ALCL 3. Bendamustine and gemcitabine for relapsed PTCL.

See more of: Practical Management of T-Cell and Natural Killer Cell Lymphomas
See more of: Education Program
<< Previous Presentation | Next Presentation >>